Wallisch M, El Rody NM, Huang B, Koop DR, Baker JR Jr, Olsen GD.
Respir Physiol Neurobiol. 2011 Oct 19.
Comment: I don't usually include animal studies, but this was intriguing. Authors developed a depot pro-drug of naloxone that is released in the setting of hypoxemia - that is, when there's a low-level of oxygen in the blood naloxone is released, reversing the (presumed) opiate effect.
Paulozzi LJ, Kilbourne EM, Shah NG, Nolte KB, Desai HA, Landen MG, Harvey W, Loring LD.
Pain Med. 2011 Oct 25. doi: 10.1111/j.1526-4637.2011.01260.x.
Comment: Our understanding of opioid analgesic deaths is so poor for many reasons - most notably it is hard to study this population because they are hidden. The authors here used a case-control design (I can't access the full article and their methods are not so well-described in the abstract) to identify risk factors for death. They found receipt of prescriptions for selected opioids and >40mg morphine equivalents daily to be substantial risk factors for overdose death. This is consistent with earlier studies.